These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6641619)

  • 1. Abstracts from the symposium Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Paris, October 26-28, 1983.
    Encephale; 1983; 9(2 Suppl 1):1A-98A. PubMed ID: 6641619
    [No Abstract]   [Full Text] [Related]  

  • 2. [Monoamine oxidase and its inhibition (author's transl)].
    Gérardy J
    J Pharm Belg; 1980; 35(2):133-42. PubMed ID: 7391926
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
    Sandler M; Glover V; Clow A; Jarman J
    Adv Neurol; 1993; 60():238-41. PubMed ID: 8420141
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoamine oxidase-B inhibition in Alzheimer's disease.
    Riederer P; Danielczyk W; Grünblatt E
    Neurotoxicology; 2004 Jan; 25(1-2):271-7. PubMed ID: 14697902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of monoamine oxidase inhibitors.
    Youdim MB; Edmondson D; Tipton KF
    Nat Rev Neurosci; 2006 Apr; 7(4):295-309. PubMed ID: 16552415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions with reversible monoamine oxidase-A inhibitors.
    Callingham BA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S42-50. PubMed ID: 8313396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 8. A neuroscientific update on monoamine oxidase and its inhibitors.
    Schwartz TL
    CNS Spectr; 2013 Dec; 18 Suppl 1():25-32; quiz 33. PubMed ID: 24252505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics of the disordered regulation of monoamine oxidase activity in pathological states and the regulatory role of the monoamine oxidases].
    Gorkin VZ
    Vestn Akad Med Nauk SSSR; 1986; (8):8-13. PubMed ID: 3532612
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical pharmacology of reversible monoamine oxidase-A inhibitors.
    Bieck PR; Antonin KH; Schmidt E
    Clin Neuropharmacol; 1993; 16 Suppl 2():S34-41. PubMed ID: 8313395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mao-B inhibitor know-how: back to the pharm.
    Burke WJ
    Neurology; 2009 Dec; 73(23):2048; author reply 2048. PubMed ID: 19996086
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversible monoamine oxidase-A inhibitors in social phobia.
    Liebowitz MR; Schneier F; Gitow A; Feerick J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S83-8. PubMed ID: 8313403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of the pharmacological effect of monoamine oxidase inhibitors].
    Gorkin VZ
    Vestn Akad Med Nauk SSSR; 1984; (11):72-5. PubMed ID: 6396999
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoamine oxidase is not in synapse.
    Wild T
    Aust N Z J Psychiatry; 2007 Nov; 41(11):940. PubMed ID: 18074624
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.
    Chimenti F; Bolasco A; Manna F; Secci D; Chimenti P; Granese A; Befani O; Turini P; Alcaro S; Ortuso F
    Chem Biol Drug Des; 2006 Mar; 67(3):206-14. PubMed ID: 16611214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 19. On the role of monoamine oxidase-A for the maintenance of the volitional consumption of ethanol in two different rat models.
    Mega BT; Sheppard KW; Williams HL; McMillen BA
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):319-26. PubMed ID: 12237745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants.
    Murphy DL; Garrick NA; Aulakh CS; Cohen RM
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):37-43. PubMed ID: 6735994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.